Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ELWT vs LMRI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ELWT Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 6–2 Matrix Metrics)

ELWT Overall Winner 6-Pillar Tally: ELWT 4 – 0 LMRI (2 Tie) Matrix Metrics: ELWT 6 – 2 LMRI

As of Nov 20, 2026, ELWT (ELWT) is the stronger overall head-to-head candidate over LMRI (LMRI) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ELWT carries a Unified Composite Score of 51.7/100 (HOLD) at $2.97 (N/M Forward P/E, -55.0% operating margin), whereas LMRI carries 32.1/100 (SELL) at $14.26 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: ELWT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 23.3); meanwhile LMRI trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ELWT vs LMRI
ELWT US Equity Head-to-Head Winner
ELWT
Institutional Equity
$2.97
-2.94% 1D
Market Cap $20.3M
TTM Revenue $19M
Forward P/E N/M
Beta / 30D Vol 1.20β · 88% Vol
Unified Composite Score
51.7 / 100 HOLD
Tech 60.0 Fund 52.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -21.6%), weak momentum, RSI 23
RSI-14: 23.3 · SMA20: $3.83 · SMA50: $5.37
LMRI US Equity
LMRI
Institutional Equity
$14.26
+1.42% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.22β · 85% Vol
Unified Composite Score
32.1 / 100 SELL
Tech 50.0 Fund 30.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.4% over 20 days), RSI 63
RSI-14: 62.5 · SMA20: $13.28 · SMA50: $11.73

6-Pillar Scorecard Institutional Category Breakdown (ELWT 4 – 0 LMRI)

Columns: Metric · ELWT · LMRI
1. Valuation Multiples ELWT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 1.1x N/M
2. Growth & Scale ELWT
Revenue Growth (YoY) +6.6% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $19M N/A
Market Cap $20.3M N/A
3. Profitability & Quality ELWT
Gross Margin 10.0% N/A
Operating Margin -55.0% N/A
Net Profit Margin -55.6% N/A
Return on Equity (ROE) 0.0% N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage 0.0% ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat ELWT
OpEx & R&D Intensity 65.0% of Rev ($12M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Telecom Services Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ELWT (6) vs LMRI (2)
Institutional Metric ELWT LMRI Criterion Row Edge
Market Capitalization
Scale
$20.3M N/A Larger Scale ELWT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+6.6% N/A Higher Growth ELWT
Operating Margin (TTM)
Profitability
-55.0% N/A Higher Margin ELWT
Net Profit Margin
Profitability
-55.6% N/A Higher Margin ELWT
Return on Equity (ROE)
Capital Efficiency
0.0% N/A Higher ROE ELWT
52-Week Range Position
Momentum
5% ($3–$10) 60% ($6–$19) Stronger Trend LMRI
Beta / 30D Volatility
Risk Regime
1.20β · 88% Vol 1.22β · 85% Vol Lower Realized Risk LMRI
Unified Institutional Score
Composite Signal
51.7 / 100 (HOLD) 32.1 / 100 (SELL) Higher Composite ELWT
Trailing 12M Revenue (USD)
Operating Scale
$19M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
10.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (0.0% ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LMRI +75.9 pp
ELWT: -44.95% · LMRI: +30.95%
3M Horizon LMRI +80.85 pp
ELWT: -60.51% · LMRI: +20.34%
6M Horizon LMRI +166.35 pp
ELWT: -62.64% · LMRI: +103.71%
1Y Horizon LMRI +29.56 pp
ELWT: -52.56% · LMRI: -23.0%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ELWT vs LMRI. Trailing 12-month operating profitability (ELWT -55.0% vs LMRI N/A) and valuation multiples (ELWT N/M vs LMRI N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ELWT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$19M
Gross Margin10.0%
Op. Margin-55.0%
ROE / Fwd P/E0.0% · N/M
LMRI ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ELWT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ELWT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LMRI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LMRI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ELWT Moat Profile Cyclical / Execution-Driven Positioning
Telecom Services Operator
Competes within the Telecom Services value chain with $20.3M market capitalization and -55.0% operating margin.
OpEx & R&D Reinvestment 65.0% of Rev ($12M)
90D Engineering Disclosures 0 Published
LMRI Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ELWT vs LMRI Key Questions & Quantitative Answers

As of Nov 20, 2026, ELWT (ELWT) is the stronger overall head-to-head candidate over LMRI (LMRI) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ELWT carries a Unified Composite Score of 51.7/100 (HOLD) at $2.97 (N/M Forward P/E, -55.0% operating margin), whereas LMRI carries 32.1/100 (SELL) at $14.26 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: ELWT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 23.3); meanwhile LMRI trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ELWT leads the Growth & Scale pillar: ELWT posts +6.6% YoY revenue growth and +0.0% YoY earnings growth on $19M TTM revenue (10.0% gross margin, -55.0% operating margin), compared with LMRI at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, ELWT generates $19M in USD-normalized revenue versus N/A for LMRI. In operating R&D and SG&A reinvestment, ELWT deploys 65.0% of Rev ($12M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LMRI.

ELWT screens cheaper on headline valuation multiples. ELWT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (unreported cash flow margin), whereas LMRI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ELWT (0.0% ROE) versus LMRI (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, ELWT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.20β · 88% Vol realized risk). By comparison, LMRI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.22β · 85% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.